Thalomid (thalidomide) — United Healthcare
Histiocytic Neoplasms
Initial criteria
- Diagnosis of Langerhans cell histiocytosis
- OR
- Diagnosis of Rosai-Dorfman Disease
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Thalomid therapy
Approval duration
12 months